Antibiotic peptide derived from helicobacter pylori ribosomal protein L1 and uses thereof
US9463214B2 · kind B2 · utility
2Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 1, 2015 |
| Grant date | Oct 11, 2016 |
| Priority date | — |
| Expiry date | Jul 1, 2035 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a peptide derived from the Helicobacter pylori ribosomal protein L1, and the use of this peptide an antibiotic. More specifically, the peptide is derived by making site-specific substitution mutations in a peptide consisting of amino acids 2-20 of the Helicobacter pylori ribosomal protein L1. The resulting peptide has both antibacterial activity and anti-inflammatory activity, but no cytotoxicity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.